Pelthos Therapeutics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $80.4M
- Price
- $20.99
- % Change (Daily % change from the live per-ticker quote feed.)
- -2.28%
- Volume
- 17.7K
About
Pelthos Therapeutics Inc. operates as a biopharmaceutical enterprise dedicated to developing and commercializing innovative medical treatments that address significant, unmet patient needs. Its primary offerings include ZELSUVMI, a medication specifically indicated for the treatment of molluscum contagiosum in individuals aged one year and older. Furthermore, the company leverages NITRICIL, an exclusive technological platform grounded in nitric oxide research. Established in 2002, this Durham, North Carolina-based firm was previously known as Channel Therapeutics Corporation, before rebranding to Pelthos Therapeutics Inc. in July 2025.
Quick stats
Shares outstanding3.8M
Computed float1.4M
Float / shares36.3%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001919246
Websitehttps://pelthos.com
AI Summary
AI-generated1/11
standardbullishoperations update
Pelthos Therapeutics Announces Expanded Formulary Coverage for ZELSUVMI® (berdazimer) Topical Gel, 10.3%
Pelthos Therapeutics signed an agreement with a major PBM to add ZELSUVMI to its national formulary covering 24 million lives, without prior authorization, effective October 1, 2026.
A regional health plan update added roughly 3 million more covered lives, bringing commercial formulary coverage to 127 million lives, or 69% of the commercial market, with Medicaid coverage above 70 million lives.
Expanded access is a key commercial driver for ZELSUVMI, launched in July 2025 as the only at-home prescription therapy for molluscum contagiosum.